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Background: Patients trying life-preserving agents such as beta-blockers may be discouraged by listings of harmful
effects provided in good faith by doctors, drug information sheets, and media. We systematically review the world
experience of side-effect information in blinded, placebo-controlled beta-blockade in heart failure. We present in-
formation for a physician advising a patient experiencing an unwanted symptom and suspecting the drug.
Methods:We searchedMedline for double-blinded randomized trials of beta-blocker versus placebo in heart failure
reporting side-effects. We calculated, per 100 patients reporting the symptom on beta-blockade, howmany would
have experienced it on placebo: the “proportion of symptoms non-pharmacological”.
Results: 28 of the 33 classically-described side-effects are not signiﬁcantly more common on beta-blockers than
placebo.
Of the 100 patients developing dizziness on beta-blockers, 81 (95% CI 73–89)would have developed it on placebo.
For diarrhoea this proportion is 82/100 (70–95), and hyperglycaemia 83/100 (68–98). For only two side-effects is
this under half (i.e. predominantly due to beta-blocker): bradycardia (33/100, CI 21–44) and intermittent claudi-
cation (41/100, 2–81).
At least 6 so-called side-effects are less common on beta-blocker than placebo, including depression (reduced by
35%, p b 0.01) and insomnia (by 27%, p = 0.01).
Conclusions: Clinicians might reconsider whether it is scientiﬁcally and ethically correct to warn a patient that a
drug might cause them a certain side-effect, when randomized controlled trials show no signiﬁcant increase, or
indeed a signiﬁcant reduction. A better informed consultation could, in patients taking beta-blockers, alleviate
suffering. In patients who might otherwise not take the drug, it might prevent deaths.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.1. Introduction
Beta-blockers greatly improve survival in chronic heart failure [1,2]
but only in patientswho take them.Uptake is poor [3] and not improving
[4]. One contributor is perception amongst patients and physicians of
side-effects.om the BritishHeart Foundation
irculatory Health, Imperial Col-
. Tel.: +44 207 594 1093; fax:
Barron).
eliability and freedom from bias
Ireland Ltd. Open access under CC BYPatient experience of side-effects may be an unreliable guide to the
true pharmacological induction of side-effects by the drug because, in
real life, drugs are not administered in an information vacuum. Instead,
well-intentioned forewarning of potential side-effects by clinicians con-
ditions patients to believe any new symptom is a drug side-effect, even if
it is really due to heart failure itself or a coincidental problem. Side-
effects described in drug information leaﬂets and ofﬁcial online informa-
tion [5] are listed in Table 1.
Information not available to patients, and not realistically available to
front line doctors, is careful delineation of which side-effects have reli-
able evidence of induction by beta-blockers, in patients with heart fail-
ure. Even more helpful would be to be ability to discuss quantitatively,
with patients reporting a listed side-effect, the probability that they are
experiencing a genuine consequence of the drug rather than spontane-
ous phenomena or nocebo (the undesirable ﬂip-side of placebo).
In this studywe examine the only reliable source of this information:
double-blinded randomized controlled trials (RCTs) in which doctors
and patients reported side-effects without knowing whether the patient-NC-SA license.
Table 1
Example listing of side-effects of beta-blockers. This is the information on side effects given to patients and their physicians according to drug information leaﬂets and the electronic
Medicines Compendium website (http://www.medicines.org.uk/emc).
Beta-blocker related side-effects
Cardiovascular Bradycardia, interferencewith normal heart rate, irregular heart rate, slowed atrio-ventricular conduction, atrio-ventricular block, palpitations, cardiac
failure, hypotension, orthostatic hypotension, angina, oedema, ﬂuid overload, hypervolaemia, disturbances of peripheral circulation (cold extremities,
peripheral vascular disease, exacerbation of intermittent claudication, gangrene in patients with poor circulation and Raynaud's phenomenon)
Respiratory Dyspnoea, shortness of breathwith orwithout strenuous physical activity, bronchospasm,wheeze, asthma in predisposed patients, nasal congestion, runny
nose, ﬂu like symptoms, bronchitis, pneumonia, upper respiratory tract infection
Gastro-intestinal Abdominal pain, dry mouth, nausea, vomiting, constipation, diarrhoea, dyspepsia, ﬂatulence, upset stomach, hepatitis and deranged liver enzymes
Genito-urinary Impotence, disturbances of sexual desire and performance, erectile dysfunction renal failure and renal function abnormalities in patients with diffuse
vascular disease and/or underlying renal insufﬁciency, micturition disorders, urinary incontinence in women, urinary tract infection
Neurological Tiredness, dizziness, depression, depressed mood, headache, pre-syncope, syncope, fainting paraesthesia, tingling or pins and needles, muscle cramps,
muscle weakness, sleep disorders, nightmares, asthenia, inability to think clearly, sleepiness or difﬁculty sleeping, change in personality, hallucinations,
hearing impairment
Skin & subcutaneous tissues Skin reactions e.g. sensitivity to light, allergic exanthema, dermatitis, hypersensitivity reactions, angioedema, increased sweating, urticaria, pruritus,
psoriatic and lichen planus like skin lesions, alopecia, worsening of existing psoriasis
Metabolism & nutrition Dyslipidaemia, hypercholesterolemia, weight gain, impaired blood glucose control, deranged blood glucose control in existing diabetics
Haematological Changes in blood results including anaemia, thrombocytopenia and leucopoenia, effects on blood clotting causing unexplained or easy bruising,
worsening or new blood vessel disorders
Musculoskeletal Joint inﬂammation, pain in extremities, myasthenia gravis
Eye disorders Visual impairment, decreased lacrimation and dry eyes, eye irritation, conjunctivitis
3573A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579was taking the drug or placebo. The increment in side-effects genuinely
caused by the drug can therefore be seen.
This systematic review is the ﬁrst to present reliable values, for each
listed side-effect, of the proportion of heart failure patients who report
it in which the beta-blocker is truly the cause, using comprehensive
data from RCTs of placebo versus beta-blocker therapy in systolic
heart failure. It extends upon previous analyses [6] by covering a more
extensive set of studies, by intentionally using an analysis that is easily
replicated by a physician laterwanting to add data of trials not currently
available, and by deliberately presenting information in a format as
helpful as possible to clinicians and patients handling the situation of
a suspected side-effect.
2. Methods
2.1. Search method
We carried out a systematic review of studies that evaluated side-effects noted in RCTs
in patients with systolic heart failure in accordance with published guidelines [7]. Between
November 2010 and 8 November 2011 we searched Medline (1950 to present) using the
keywords beta-blocker, systolic heart failure, randomized controlled trial and RCT, accessi-
ble in English. We excluded letters, abstracts, systematic reviews and meta-analyses. Two
independent reviewers (NZ, AB) screened the titles, assessing for eligibility by abstractFig. 1. An example of how the proportion of symptoms non-pharmacological has been calcu
100 patients with heart failure. The open circles show how many would expect to experienc
would experience the side effect if all 100 took the drug. From this the physician and the pa
proportion of circles that are open. The spreadsheet that calculates these proportions, and au
(www.libreofﬁce.org) or the widely-available Microsoft Excel. It is downloadable as an Onlreview to determine satisfaction of the selection criteria, before retrieving selected titles.
Any disagreements were resolved through consensus or consultation with a third reviewer
(DF). Reference lists of the retrieved articles were searched for additional publications.
Follow-up length was not speciﬁed by our review protocol. Each article was fully reviewed
for data including total number of patients in each arm, and number of patients exhibiting
each side-effect in the beta-blocker and the placebo arm separately. The authors of this
manuscript have certiﬁed that they comply with the Principles of Ethical Publishing in
the International Journal of Cardiology.
2.2. Inclusion/exclusion criteria
We identiﬁed parallel-group RCTs comparing a single beta-blocker versus placebo.
Trials were excluded if they were not randomized double-blinded studies; had cross-over
design; did not report side-effect data separately for beta-blocker and placebo arms; or if
other (heart failure) medications were selectively introduced as part of study protocol.
2.3. Analysis
We listed side-effects, 33 in total, that were assessed for presence in more than 100
patients across all eligible studies. We have used the phrase “listed side-effect” to indicate
a symptom listed by at least one RCT as a side-effect, regardless of whether our ﬁnal results
indicate that the drug increased, did not affect, or even decreased the rate. Because some
studies reported side-effects that others did not, the denominator number of patients dif-
fered between side-effects. Funnel plots were constructed for 10 of the listed side-effects
which in the majority show an acceptable distribution. These results are shown in Supple-
mentary Fig. 1.lated for a single listed side-effect on beta-blocker therapy. The square chart represents
e the side effect without the drug. The ﬁlled circles show how many additional patients
tient can visualise the proportion of side effects that are non-pharmacological: it is the
tomatically displays the square chart, operates on the free and open-source LibreOfﬁce
ine Supplement of this article.
Table 2
Description of trials included in this study.
Trial N Treatment
groups
Clinical setting Total mortality
(%)
Mean
follow-up
(months)
Run-in period Reported outcome
Drug Placebo
CIBIS 641 Bisoprolol vs
placebo
NYHA III–IV, EF ≤ 40% 16.6 20.8 22.8 No Increasing β-blocker dose in severe HF confers
functional beneﬁt
CIBIS-II 2647 Bisoprolol vs
placebo
NYHA III–IV, EF ≤ 35% 11.8 17.3 15.6 No Bisoprolol reduces mortality in CHF patients at
all tolerated dose levels
BEST 2708 Bucindolol vs
placebo
NYHA III–IV, EF ≤ 35% 30.0 33.0 24 No Bucindolol results in no signiﬁcant overall
mortality beneﬁt in HF patients
CAPRICORN 1959 Carvedilol vs
placebo
Post MI, EF ≤ 40%
On ACE-I
11.9 15.4 15.6 No Carvedilol reduces all-cause and cardiovascular
mortality, and recurrent, non-fatal myocardial
infarctions.
COPERNICUS 2289 Carvedilol vs
placebo
NYHA III–IV, EF ≤ 25%
On ACE-I
12.8 19.7 10.4 No Carvedilol reduces mortality by 34% in HF
patients, ameliorates severity of HF
PRECISE 278 Carvedilol vs
placebo
NYHA III–IV, EF ≤ 35% N/A N/A 6 Open-label
carvedilol
Carvedilol produces important clinical beneﬁts
in patients with moderate–severe HF
US Heart Failure
Study Group I
366 Carvedilol vs
placebo
NYHA III–IV, EF ≤ 35% 0.9 4.0 12 Open-label
carvedilol
Carvedilol reduces clinical progression in mildly
symptomatic, well compensated HF patients
Krum et al. 49 Carvedilol vs
placebo
NYHA III–IV, EF ≤ 35% 6.0 18.0 3.5 Open-label
carvedilol
Carvedilol produces clinical & haemodynamic
improvement in severe HF
MERIT-HF 3991 Metoprolol vs
Placebo
NYHA II–IV, EF ≤ 40% 7.2 11.0 12 Single-blind
placebo
Metoprolol in addition to optimum standard
therapy improves survival in HF patients
The MDC study 383 Metoprolol vs
placebo
NYHA II–III, EF ≤ 40%
From idiopathic dilated
cardiomyopathy
11.9 11.1 12 Open-label
metoprolol
Metoprolol prevents clinical deterioration,
improves symptoms and cardiac function in
idiopathic dilated cardiomyopathy
SENIORS 2128 Nebivolol vs
placebo
EF ≤ 35% or HF
hospitalisation
in last 12 months
15.8 18.1 21 No Nebivolol is an effective and well tolerated
β-Blocker in the elderly
Wisenbaugh et al. 44 Nebivolol vs
placebo
EF ≤40%, NYHA II–III N/A N/A 3 Placebo
(patients replaced)
Nebivolol improves stroke volume, EF and
LVEDP
MOCHA study 345 Carvedilol vs
placebo
EF ≤35%, NYHA II–III 4.6 15.5 6 Open-label carvedilol Carvedilol improves mortality and risk of
hospitalisations in HF patients
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Tests for heterogeneitywere employed, and because of heterogeneity between trials in
some side-effects, a random-effects, rather than ﬁxed-effects, model was used to evaluate
the difference in event rate between arms in the trials. Comprehensive Meta Analysis soft-
ware package, Version 2.2.057, was used. The z-score and conﬁdence interval of difference
were calculated by standard methods.
.2.3.2. Simple analysis, replicable by any reader
In parallel a simple analysiswas employed. This secondary analysis, presented as a sup-
plemental ﬁle, is designed to be conceptually simple and arithmetically straightforward soFig. 2. PRISMA ﬂow diagram of the studies.that it could be easily be followed and replicated by anyonewishing to recheck the ﬁndings
or update itwith future primary data, or explain it to a patient. It is based on simple addition
of numbers of patients enrolled in corresponding arms, and numbers with side-effects. The
excess event rate in the drug arms was calculated by straightforward subtraction: rate in
beta blocker armsminus rate in placebo arms. A negative value indicated that the symptom
was less frequent in the drug arms than the placebo arms..2.3.3. Proportional of symptoms non-pharmacological
We calculated per 100 beta-blocker recipients describing that symptom, how
many would have had that symptom on placebo. This “proportion of symptoms
non-pharmacological”was calculated for each listed side-effect. Fig. 1 shows an exam-
ple of how this is calculated, and offers one simple way of displaying the results. TheFig. 3. The proportions of patients where beta-blocker is causative (± conﬁdence intervals)
for 5 side-effects statistically more prevalent in the beta-blocker arm of RCTs.
Table 3
Formal random-effects meta-analysis of the principal analysis (green denotes signiﬁcantly more common in the placebo arm, amber denotes no signiﬁcant difference between arms, and
red signiﬁcantly more common in the active drug arm). The proportion of symptoms non-pharmacological has been shown alongside this analysis (see Methods for calculation of this
value).
Side-effect Effect size and 95% interval Test of null (2-Tail) Number of patients
(from 100
presenting with a
symptom) where
Beta-blockers are
NOT causativePoint estimate Lower limit Upper limit Z-value P-value
Tachycardia 0.518281 0.413645 0.649386 −5.7122 0.000
Palpitations 0.712785 0.553098 0.918577 −2.6162 0.009
Depression 0.72055 0.561046 0.9254 −2.5673 0.010
Insomnia 0.758349 0.608176 0.945603 −2.4567 0.014
Cardiac failure 0.694798 0.556296 0.867782 −3.2102 0.001
Chest pain 0.800591 0.693194 0.924628 −3.0263 0.002
Nausea 1.414402 0.660837 3.027273 0.8930 0.372
Unstable angina 0.67559 0.424112 1.076182 −1.6509 0.099
Pneumonia 0.69845 0.406139 1.201145 −1.2974 0.194
Bronchitis 0.671762 0.202397 2.229595 −0.6500 0.516
Vomiting 0.900001 0.729547 1.110281 −0.9835 0.325
Hypertension 0.875701 0.60281 1.27213 −0.6967 0.486
Renal impairment 0.806366 0.412185 1.57751 −0.6286 0.530
Syncope 0.992266 0.787619 1.250086 −0.0659 0.947
Headache 1.112715 0.754139 1.641784 0.5381 0.590
Abdominal pain 1.022958 0.839855 1.24598 0.2256 0.822
Anaemia 0.967067 0.609964 1.533235 −0.1424 0.887
Impotence 0.975447 0.630081 1.510119 −0.1115 0.911
Oedema 1.54966 0.728607 3.295941 1.1376 0.255 >99
Anorexia 1.017501 0.824116 1.256265 0.1613 0.872 99
Weight increase 1.212673 0.918669 1.600768 1.3612 0.173 94
Fatigue 1.07301 0.945909 1.217188 1.0955 0.273 94
TIA 1.09255 0.609594 1.958131 0.2973 0.766 92
Hypotension 1.226011 0.916276 1.640448 1.3715 0.170 92
Postural hypotension 1.131948 0.879632 1.456639 0.9632 0.335 89
Dyspnoea 0.848755 0.689807 1.044329 −1.5450 0.121 89
Nasopharyngitis 1.268411 0.802288 2.005348 1.0174 0.309 80
Asthenia 1.75 0.583236 5.250876 0.9982 0.318 59
Hyperglycaemia 1.313181 1.082524 1.592986 2.7646 0.006 83
Diarrhoea 1.400816 1.176932 1.667287 3.7935 0.000 82
Dizziness 1.454969 1.171747 1.806648 3.3945 0.001 81
Claudication 2.465368 1.316957 4.615216 2.8206 0.005 41
Bradycardia 3.449837 2.194331 5.423692 5.3643 0.000 33
3575A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579spreadsheet used to produce Fig. 1 is freely downloadable in the Online-only supplement.
The result is shown in the ﬁnal column of Table 3.
Total adverse events and withdrawals due to supposed adverse side-effects or (if those
speciﬁc data were not available) total withdrawals were also calculated.
Beta-blockers included carvedilol and bucindolol (non-selective) and metoprolol,
bisoprolol andnebivolol (selective).We performed sensitivity analyses to assess for inher-
ent differences in side-effect proﬁles between these two subclasses.
Run-in periods (identiﬁed in Table 2) were excluded because the data including the
whole cohort prior to a run-in period was almost never disclosed. Most studies present
the results of an up-titration phase and a subsequent maintenance phase together but
in some, where side-effects were described separately, we have included only those
seen in the maintenance phase, to avoid the risk of double-counting.
Chi-squared analysiswith threshold of p b 0.05was used to determinewhether there
was a signiﬁcant difference in rate between drug and placebo arms.3. Results
3.1. Study characteristics
Of the 319 studies screened, thirteen RCTswere included in the ﬁnal
analysis [1,2,8–18] (Fig. 2). Table 2 shows a summary of all these trials.
These include up to 7836 patients in the beta-blocker arm, and 7547 pa-
tients in the placebo arm for the 33 listed side-effects. Only two studies
describe that side-effects were actively discussed at each follow-up visit
[10,16] otherwise it is unclear whether the occurrence of side-effects
was solicited or gathered through spontaneous self-reporting. Thestudies that listed depression as a side-effect did not report how this
was validated.
3.2. Frequency of side-effects
For 3 side-effects (worsening heart failure, oedema and bradycardia)
there was signiﬁcant heterogeneity between studies so, for all side-
effects, a random-effects model was employed. The p values listed are
from this principal analysis. A corresponding table showing the results
from the secondary analysis is shown in the Online Supplementary
Table 1.
There was no signiﬁcant difference in the frequency of side-effects
between arms for most (21 of 33) listed side-effects. Examples of listed
side-effects in this group included impotence, weight gain, postural hy-
potension and headache; they are shaded yellow in Table 3.
Depression (p b 0.01) and insomnia (p = 0.01), along with worsen-
ing heart failure (p b 0.01), palpitations (p b 0.01), chest pain (p b 0.01)
and tachycardia (p b 0.01), were signiﬁcantly less frequent in the beta
blocker arm in the principal analysis and are shaded green in Table 3.
Broadly similar results were seen in the secondary analysis (Online
Supplement Table). Nausea was less common in the beta-blocker arm,
in the secondary analysis, but the formal meta-analysis showed no sig-
niﬁcant difference between arms; this was the only listed side-effect
with a discrepancy in category (colour code) between the two analyses.
Fig. 4. Forest Plot of 5 frequently discussed perceived side-effects of beta-blocker use — fatigue, hypotension, hyperglycaemia, dizziness and bradycardia.
3576 A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579Only 5 of 33 listed side-effects are signiﬁcantly more common in
the beta-blocker arm, shown with red p-values in Table 3. These are
considered further in Fig. 3, which shows that, even for these 5
side-effects, in many patients it is not the drug that is the cause.
Out of 100patients on beta-blockers developing dizziness, a common-
ly discussed side-effect of beta-blockade, 81 (95% conﬁdence intervals
73–89 patients, p b 0.01), would have had that symptom on placebo;
either arising naturally or from the warnings given (i.e. beta-blockers
are only causative in 19 from every 100 patients). For diarrhoea
this proportion was 82 from 100 patients (95% CI 70–95, p b 0.01).
For hyperglycaemia this proportion was 83 (CI 68–98, p b 0.01), for
intermittent claudication 41 (CI 2–81, p b 0.01), and for bradycardia
33 (CI 21–44, p b 0.01).
Forest Plots for 5 frequently discussed side-effects can be viewed
in Fig. 4.
Drug withdrawal data were formally presented in 6 out of 13 trials.
Randomization to beta-blocker did not signiﬁcantly increase the risk ofwithdrawal, with a 20% relative reduction compared with placebo
(Fig. 5A).
Serious adverse events were formally presented in 2 out of 13 trials
and occurred in 22.1% of patients receiving beta-blocker and 25.6% of
patients receiving placebo: randomization to beta blocker therefore de-
creased the risk of serious adverse events by 16% (95% CI 4–27%
p = 0.01, Fig. 5B).
3.3. Subgroup analysis by beta-blocker selectivity
For only 10 of the 33 listed side-effects were sufﬁcient data available
from trials of both selective and non-selective beta-blockers (Supple-
mentary Table 2). Results were similar between types of beta-blockers
for dizziness, bradycardia, chest pain, dyspnoea, fatigue, headache,
asthenia, and hypotension. Although both classes of beta blocker
resulted in signiﬁcantly fewer cardiac failure events in the active drug
arm, the magnitude of this difference was signiﬁcantly greater in the
Fig. 5. Forest Plot of drugwithdrawal (A) and serious adverse events (B) amongst RCTs of double-blind beta-blocker versus placebo controlled trials. Overall there are more withdrawals
and serious adverse events amongst participants in the placebo groups.
3577A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579non-selective trials. The only listed side-effect with any suggestion of
difference between the two types of beta-blockers was oedema with a
signiﬁcant increase in the drug arm of the selective beta-blocker trials
(p b 0.01), and a borderline signiﬁcant decrease in the non-selective
trials (p = 0.06), leading to overall no signiﬁcant difference between
placebo and beta-blocker amongst all trials.
4. Discussion
Medicine has become a science through recognising the existence of
spontaneous variability in disease over time, and the resulting need to
design and conduct an RCT to reliably establish whether a treatment
works. This recognition should also be applied to information given to
patients about side-effects.
Published RCTs indirectly give valuable information that is currently
rarely discussed. For any listed side-effect it is easy for a physician to cal-
culate, fromoneRCT or a set of RCTs, the proportion of thosewho suffered
a symptomwhowould have suffered it evenwithout themedication (the
PSN). The downloadable spreadsheet in the Online Supplement assists
with this, and provides a visual display that may support discussions
with patients who ﬁnd the PSN difﬁcult to understand in isolation.
4.1. Lost opportunity for prevention
The majority of adverse effects reported with beta-blockers in
heart failure are not caused by the beta-blockers per se, but arise ei-
ther from the disease itself, another coincident problem, or from the
power of suggestion — the nocebo phenomenon [19].
Althoughbeta-blockers reducemortality by about 35% inheart failure
[1,2,14], utilization is disappointing, with sustained usage being only
~50% [3]. Even when beta-blockers are started, willingness to achieve
target doses is disappointingly low [20], presumably because of fears of
provoking side-effects by uptitration, despite randomized double-blind
experience contradicting this [21]. Asymmetric discussion of the beneﬁts
and risks of therapy can be particularly damaging during uptitration.
Each clinic visit risks a fresh enquiry about side-effects, implying to the
patient that future symptoms might be assumed to be the result of the
drug. Albeit innocent, this sows the seeds for future abandonment.
In this analysis therewere only 2 of 33 listed side-effects (bradycardia
and intermittent claudication) for which the majority of sufferers had
that side-effect genuinely caused by the drug.In another 3 of the 33 side-effects, the drug was genuinely re-
sponsible in less than 1 in 4 sufferers. For example, in patients with
dizziness, a symptom commonly attributed to beta-blockade, PSN
was 81/100, i.e. beta-blockers were found to be genuinely responsi-
ble in only 19 out of 100 cases.
In the other 28 of 33 side-effects, there is no evidence that the drug
makes themmore common. These include fatigue, commonly attributed
to beta-blockade. Fatigue is very prevalent in the general healthy popula-
tion, being reported in 39% of un-medicated volunteers [22]: it is unlikely
to be less prevalent in heart failure.
4.2. Potentially lethal asymmetry
Unscientiﬁc claims of therapeutic efﬁcacy, that do not account for the
placebo effect, are rightly condemned and punished. Yet the same scru-
tiny is not yet applied to incorrect assertions of harmful effects. It would
never be permitted to claim that a drug decreased an undesirable out-
come when in fact the data showed that it increased it: it should corre-
spondingly not be permitted to warn that a drug increases a side-effect
when the data show that it decreases it.
The origin of the extensive list of side-effects may have been un-
blinded, early-phase experience where investigators were asked to doc-
ument any adverse events occurring alongside medication use, with the
focus on comprehensiveness rather than meaningfulness. Such a list can
only be interpreted alongside a parallel list of side-effects of similar pa-
tients taking placebo having been given the same warning information,
but there is no organized process for formulating this.
Incautious reports of side-effects can end up being re-reported and
advertised in lay media uncritically, discouraging initiation and encour-
aging discontinuation, ultimately causing deaths. This unjustiﬁable
asymmetry is most reliably resolved using double-blinded data from
RCTs.
4.3. Clinical and ethical implications
Well-intentioned individuals designing best-practice recommenda-
tions, speculating in isolation from day-to-day experience, may think it
superﬁcially reasonable to insist on providing patients with all informa-
tion on potential consequences of proposed therapy [23]. However if
there is no standard on what is considered a potential consequence,
Fig. 6. A rational side-effect note to give patients regarding beta blockers for heart failure. When advising patients to disregard regulatory notes because they are incorrect, it would be
useful to have a replacement note whose content is supported by the blinded placebo-controlled studies. This proposed note is designed to show the available information simply for
use by patients with heart failure.
3578 A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579then any list must necessarily be inﬁnitely long since no proposed addi-
tion can ever be refused.
Individual patients may have preferences on how they wish to be
managed on a spectrum between paternalistic medicine (told little)
and a fully informed approach (told everything) [24], but few want
information on side-effects that is invalid or – even worse –
backwards.
Physicians personally involved in proposing highly effective thera-
pies to psychologically-vulnerable patients with lethal diseases might
be forgiven for not recommending that they carefully scrutinise side-
effects lists which could be argued to contain more untruth than
truth. Instead, physicians might focus the patient's attention on a
much smaller core of reliable information, together with information
on the proportion of side-effects that are non-pharmacological. Thus
adverse effects, when later experienced, are not automatically assumed
to be caused by the drug. Fig. 6 shows a starting proposal for a replace-
ment side-effect list for heart failure patients starting beta-blocker
therapy.
Physicians may feel that in individual cases it can be clear that a
side-effect is due to the medication, and they may be right. On the
other hand it was notable in the COPERNICUS study that whilst 38% of
patients on beta-blocker required down-titration due to side-effects,
33% of patients on placebo also “required” this down-titration. As phy-
sicians we may be no less susceptible to the illusion of control than
other disciplines [25]. PSN values, such as those shown here, are a
starting point for a rational open discussion with a patient.
Some physicians also consider the legal dimension, and some-
times feel forced to make decisions to avoid litigation [26]. If, on
the one hand, the law compels the clinician to advise a patient that
a drug could cause him or her (for example) depression, whilst at
the same time the randomized blinded data show a signiﬁcant re-
duction in depression, the clinician is in a quandary. We may need
clearer language so that the scientiﬁc, clinical, and legal ﬁelds can
share the same conversation. One possible form of words to resolve
this might be that taking this medication “reduces the chances” of
depression. This highlights that depression is still possible but truth-
fully reports that its likelihood is reduced. The patient would correct-
ly understand that whilst the drug may still cause depression, if it
does so it prevents it in more patients.4.4. Limitations
This study only looked into trials of beta-blockers in heart failure
rather than hypertension, angina or arrhythmia because it is in heart
failure where the absolute survival beneﬁts of beta-blockers are most
pronounced, and inadvertent discouragement of therapies is most
prone to increase mortality. Therefore these data are only applicable to
heart failure. For other disease states, separate analysis of the appropri-
ate RCTs is needed. Although a single analysis for all diseases of all RCTs
of beta-blocker versus placebo would have more patients, it would be
difﬁcult to apply the ﬁndings conﬁdently to heart failure because, just
as therapeutic efﬁcacy of drugs may differ between disease states,
side-effects may also differ.
It is possible that there are some side-effects that are caused in
some patients and prevented in others, leaving no net effect in rate,
since RCTs are only able to identify net effect reliably. There is no
reliable method to identify in advance (a) which patients will be
symptom-free without therapy but get symptoms from therapy, and
(b) which patients will have symptoms without therapy but be
symptom-free with therapy. Without such a method, the net effect
is the main clinically useful value for side-effects — just as it is for
beneﬁts.
Provision of information and protocol for eliciting the presence of
new symptoms was not standardized across the trials. Both are
known to affect the frequency of side-effects [27]. Ideally an analysis
would correct for this, frequency of visits and information given prior
to enrolment regarding potential side-effects. Unfortunately the trial
reports did not consistently indicate how side-effect information
was collected.
The underlying RCTs recruited willing volunteers. In general these
are highly motivated, and perhaps less likely to experience or report
spontaneous events as potentially drug-related. Therefore these ﬁgures
may not be representative of clinical reality where patients enter the
heart failure population unwillingly. However, this means that real-life
clinical populations would have higher PSN values.
Trial design differed between studies, most notablywith regards to a
run-in period in which all receive placebo and some (6–12% in these
studies) drop out for various reasons including perceived side-effects.
Again this means that real-life PSN may be even higher.
3579A.J. Barron et al. / International Journal of Cardiology 168 (2013) 3572–3579There is potential for bias towards greater side-effect identiﬁcation
in the beta-blocker arm, because they lived longer and so hadmore op-
portunity to report symptoms. Yet again, this means that real-life PSN
might be even higher.
5. Conclusion
Almost all commonly listed side-effects attributed to life-saving
beta-blocker therapy in heart failure are no commoner in patients on
beta-blockers than their counterparts receiving placebo. In only 2 of
33 listed side-effects are themajority of patients experiencing a genuine
adverse effect of the drug. For a further 3, although commoner in pa-
tients taking beta-blockers, the majority of patients experience either
the natural history of their disease, or the psychological effect of being
given incorrect or incomplete drug information.
For 28 of the 33 listed side-effects, the randomized controlled trials
in heart failure do not scientiﬁcally support their listing for heart failure
patients. For at least 6, the warnings may actually be backwards, be-
cause the drug is demonstrably preventative rather than causative.
The current convention of providing misinformation may be im-
peding uptake and uptitration of these agents which would otherwise
prevent deaths.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ijcard.2013.05.068.
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